These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 19335066)

  • 1. PDGFRalpha: a new therapeutic target in the treatment of hepatocellular carcinoma?
    Oseini AM; Roberts LR
    Expert Opin Ther Targets; 2009 Apr; 13(4):443-54. PubMed ID: 19335066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma].
    Reig M; Matilla A; Bustamante J; Castells L; de La Mata M; Delgado M; Moreno JM; Forner A; Varela M
    Gastroenterol Hepatol; 2010 Dec; 33(10):741-52. PubMed ID: 20851505
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation.
    Huynh H; Choo SP; Toh HC; Tai WM; Chung AY; Chow PK; Ong R; Soo KC
    Curr Cancer Drug Targets; 2011 Oct; 11(8):944-53. PubMed ID: 21834756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Sorafenib for the treatment of HCC--the beginning of a new era in the treatment of HCC].
    Greten TF; Manns MP; Malek N
    Z Gastroenterol; 2009 Jan; 47(1):55-60. PubMed ID: 19156592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted agents and systemic therapy in hepatocellular carcinoma.
    Ang C; O'Reilly EM; Abou-Alfa GK
    Recent Results Cancer Res; 2013; 190():225-46. PubMed ID: 22941024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of hepatocellular carcinoma: beyond sorafenib.
    Chan SL; Mok T; Ma BB
    Curr Oncol Rep; 2012 Jun; 14(3):257-66. PubMed ID: 22434314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib: where do we go from here?
    Siegel AB; Olsen SK; Magun A; Brown RS
    Hepatology; 2010 Jul; 52(1):360-9. PubMed ID: 20578152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting receptor tyrosine kinase pathways in hepatocellular carcinoma.
    Huynh H; Ong RW; Li PY; Lee SS; Yang S; Chong LW; Luu DA; Jong CT; Lam IW
    Anticancer Agents Med Chem; 2011 Jul; 11(6):560-75. PubMed ID: 21554207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant therapy after curative treatment for hepatocellular carcinoma.
    Kudo M
    Oncology; 2011; 81 Suppl 1():50-5. PubMed ID: 22212936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular mechanisms of sorafenib action in liver cancer cells.
    Cervello M; Bachvarov D; Lampiasi N; Cusimano A; Azzolina A; McCubrey JA; Montalto G
    Cell Cycle; 2012 Aug; 11(15):2843-55. PubMed ID: 22801548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma.
    Tai WT; Cheng AL; Shiau CW; Huang HP; Huang JW; Chen PJ; Chen KF
    J Hepatol; 2011 Nov; 55(5):1041-8. PubMed ID: 21354226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New possibilities of targeted therapy in the treatment of hepatocellular carcinoma with the help of molecular biology].
    Hagymási K; Tulassay Z
    Orv Hetil; 2010 Oct; 151(43):1763-8. PubMed ID: 20940115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
    Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M
    Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymeric nanoparticle-encapsulated hedgehog pathway inhibitor HPI-1 (NanoHHI) inhibits systemic metastases in an orthotopic model of human hepatocellular carcinoma.
    Xu Y; Chenna V; Hu C; Sun HX; Khan M; Bai H; Yang XR; Zhu QF; Sun YF; Maitra A; Fan J; Anders RA
    Clin Cancer Res; 2012 Mar; 18(5):1291-302. PubMed ID: 21868763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development.
    Ranieri G; Gadaleta-Caldarola G; Goffredo V; Patruno R; Mangia A; Rizzo A; Sciorsci RL; Gadaleta CD
    Curr Med Chem; 2012; 19(7):938-44. PubMed ID: 22214462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developing better treatments in hepatocellular carcinoma.
    Duffy A; Greten T
    Expert Rev Gastroenterol Hepatol; 2010 Oct; 4(5):551-60. PubMed ID: 20932140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
    Huynh H; Ngo VC; Koong HN; Poon D; Choo SP; Toh HC; Thng CH; Chow P; Ong HS; Chung A; Goh BC; Smith PD; Soo KC
    J Hepatol; 2010 Jan; 52(1):79-87. PubMed ID: 19910069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Targeted therapies in hepatocellular carcinoma].
    Bouattour M; Marijon H; Dreyer C; Faivre S; Raymond E
    Presse Med; 2010; 39(7-8):753-64. PubMed ID: 20378303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment.
    Strumberg D
    Drugs Today (Barc); 2005 Dec; 41(12):773-84. PubMed ID: 16474853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular carcinoma: The beginning of a long journey.
    Cascinu S
    Dig Liver Dis; 2009 Oct; 41(10):707-8. PubMed ID: 19699696
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.